Ionis reports positive data from study of olezarsen for hypertriglyceridemia
This condition is characterised by fasting triglyceride (TG) levels between ≥150mg/dL and <500mg/dL.
The multicentre, double-blind, placebo-controlled Essence study was carried out with the TIMI Study Group, the company's research partner.
It enrolled 1,478 subjects aged 18 years and above diagnosed with or at risk for ASCVD, and 9% of them had fasting triglycerides of ≥500mg/dL at baseline.
Subjects received either 50mg or 80mg of olezarsen or a placebo every four weeks via subcutaneous injection for 12 months.
The primary endpoint focused on the percentage change from baseline in fasting TG levels at the six-month mark, compared to the placebo.
Key secondary endpoints were changes in TG levels at 12 months, the proportion of subjects achieving fasting TG levels of <150mg/dL, and the percentage variations in other lipid parameters against the placebo over the treatment period.
The trial, which included subjects already on standard of care, lipid-lowering medications, achieved its primary endpoint.
A significant decrease in TG levels was observed, with a placebo-adjusted 61% decrease at the 80mg monthly dose and a 58% decrease at the 50mg dose over a six-month period, compared to the placebo.
In addition, the therapy met all key secondary endpoints, with the majority of subjects achieving normal TG levels of <150mg/dL.
Olezarsen also demonstrated a favourable tolerability and safety profile in the trial.
Ionis Pharmaceuticals global cardiovascular development senior vice-president Sam Tsimikas said: 'Following the Food and Drug Administration (FDA) approval and encouraging launch of Tryngolza (olezarsen) for people living with familial chylomicronaemia syndrome (FCS), a rare, genetic form of severely elevated TGs, these data support olezarsen's potential tobenefit the much broader population of people living with severe hypertriglyceridemia (sHTG).'
The investigational RNA-targeted medicine is designed to decrease the body's apolipoprotein C III (apoC-III) production, a protein for regulating the metabolism of triglyceride in the blood.
Last November, Ionis announced the design for a pivotal Phase III trial of ION582, an investigational treatment for Angelman syndrome (AS), following discussions with the US FDA.
"Ionis reports positive data from study of olezarsen for hypertriglyceridemia" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
MobilityMD Introduces Clean, Ingredient-First Approach to Joint Comfort and Flexibility in 2025
Salt Lake City, Aug. 12, 2025 (GLOBE NEWSWIRE) — Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Joint comfort and flexibility are vital for maintaining an active, independent lifestyle — whether it's enjoying daily walks, engaging in sports, or simply moving through the day without stiffness. The conversation around joint health is shifting toward preventative, natural options that align with long-term wellness goals in 2025. MobilityMD has emerged as part of this dialogue, offering a joint support formula built on a foundation of purity, ingredient transparency, and thoughtful formulation. While it avoids overpromising results, the supplement positions itself within the growing category of wellness products designed to complement healthy movement and an active lifestyle. Discover how MobilityMD's carefully selected ingredients are shaping the conversation around joint wellness in 2025. SECTION 1: WHY INTEREST IN 'THE SECRET, PURE INGREDIENT TO SUPPORT HEALTHY JOINTS' IS SURGING IN 2025 Joint health has become a central focus for people of all ages in 2025 — from active adults looking to preserve mobility to those seeking extra support for daily comfort. This growing attention is reflected in online search trends, with Google reporting increases in queries like 'natural joint support,' 'supplements for flexibility,' and 'best ingredients for mobility.' The public is no longer just looking for quick fixes; instead, there is heightened curiosity around long-term strategies that integrate into a balanced, healthy lifestyle. Part of this shift comes from the broader wellness movement, where consumers prioritize transparency, clean sourcing, and minimal additives in the products they choose. Social media platforms, wellness podcasts, and fitness forums are filled with discussions comparing ingredient profiles, sharing personal experiences, and evaluating which formulas fit into individual health routines. MobilityMD has entered this conversation not by making sweeping claims, but by highlighting its focus on purity and thoughtful formulation. This aligns with the expectations of today's wellness-conscious consumers, who often seek products designed to complement an active lifestyle without relying on unnecessary fillers or synthetic additives. SECTION 2: MOBILITYMD'S INGREDIENT-FIRST RESPONSE TO THESE TRENDS MobilityMD was developed with a clear focus on sourcing and formulation choices that align with the modern consumer's expectations for clean, purposeful supplementation. Rather than relying on heavily processed or synthetic compounds, the formula incorporates naturally derived ingredients that have been historically discussed for their association with mobility and joint comfort. Each component is chosen with the intent to complement an active lifestyle while avoiding unnecessary additives that do not contribute to the product's purpose. The ingredient selection process emphasizes purity and transparency. This includes providing clear information about sourcing, composition, and function so that consumers can make informed choices about what they put into their bodies. The formulation also considers how different ingredients work together, aiming for a balanced profile that fits into a variety of health routines — from daily wellness habits to more targeted mobility-focused regimens. Importantly, MobilityMD avoids making direct medical claims. Instead, it positions itself as part of a broader wellness strategy, one that supports consumers in pursuing movement-friendly lifestyles while staying mindful of ingredient integrity. Discover how MobilityMD's ingredient transparency reflects the growing demand for cleaner, more purposeful joint support supplements. SECTION 3: INGREDIENT SPOTLIGHT – WHAT'S INSIDE THE FORMULA The foundation of MobilityMD lies in a carefully curated selection of naturally derived ingredients, each frequently discussed in wellness circles for their historical associations with joint comfort and mobility. While the product avoids making direct health claims, it draws on a blend that reflects both tradition and modern supplement formulation trends. Key components often include botanical extracts that have been explored for their potential to support overall wellness, minerals that play a role in maintaining balanced body functions, and naturally occurring compounds that have been studied for their relevance to healthy aging. Each ingredient is chosen with attention to purity, potency, and its ability to integrate seamlessly into a daily health regimen. MobilityMD also emphasizes the importance of what's left out of the formula. There are no unnecessary fillers, artificial colors, or synthetic preservatives — a choice that resonates with consumers who are mindful of every element they consume. This focus on clean composition positions the supplement within the growing category of wellness products designed for individuals who prioritize ingredient integrity as much as potential functional benefits. SECTION 4: WHAT REDDIT, PODCASTS & TIKTOK CREATORS ARE SAYING Conversations about joint health supplements have expanded well beyond traditional advertising channels in 2025. On Reddit, wellness and fitness communities are filled with discussions about ingredient quality, transparency, and the importance of long-term consistency in supplementation. Users frequently share their experiences with products that align with clean-label trends, and MobilityMD has been mentioned in threads that focus on naturally derived joint support options. Podcasts in the health and wellness space often highlight how consumers are becoming more discerning about supplement choices. Guests on these shows frequently emphasize reading ingredient labels, understanding sourcing, and looking for products that complement an active lifestyle. MobilityMD's ingredient-focused approach aligns with these ongoing discussions, making it a relevant part of broader wellness dialogues. On TikTok, creators in the fitness, yoga, and lifestyle categories are producing short-form content around joint-friendly routines, mobility exercises, and supplement habits that fit into a balanced regimen. While these creators don't make specific claims about results, they often showcase how clean-label supplements can be integrated alongside movement practices to support overall wellness. Learn why MobilityMD is appearing in more conversations about clean, transparent joint support in 2025. SECTION 5: WHO MIGHT BE DRAWN TO THIS TYPE OF SUPPLEMENTATION IN 2025 MobilityMD appeals to a wide range of individuals who prioritize maintaining joint comfort and flexibility as part of their overall wellness goals. Active adults, including those who enjoy walking, hiking, yoga, or recreational sports, may be drawn to the idea of a supplement that aligns with their lifestyle without unnecessary additives. Professionals who spend long hours sitting or standing may also find the clean-label approach appealing, as they look for ways to support movement and ease in daily routines. Similarly, older adults seeking to remain active and independent often look for supplements with a transparent ingredient list that avoids synthetic fillers or artificial preservatives. The eco-conscious and health-conscious crowd is another natural audience for MobilityMD. For these individuals, supplement choice is about more than potential functional benefits — it's about knowing that the formula is built on pure, purposeful components. This aligns with the broader wellness movement of 2025, where consumers increasingly value products that support their personal health goals while also reflecting their ethical and environmental values. SECTION 6: EMERGING WELLNESS & PERFORMANCE INNOVATION – 2025 MARKET REFLECTIONS The wellness and supplement market in 2025 reflects a distinct shift toward ingredient transparency, clean-label formulations, and products that fit seamlessly into long-term health routines. Consumers are increasingly skeptical of overpromising claims and are instead prioritizing supplements that are clear about their composition and intended role in a balanced lifestyle. This has created a strong market for products like MobilityMD, which position themselves as part of a broader wellness toolkit rather than a one-step solution. This trend is driven in part by the rise of self-education in health and nutrition. With more information available online than ever before, people are researching ingredients, comparing labels, and making purchasing decisions based on both scientific discussion and personal values. Social media platforms, wellness blogs, and community forums all contribute to this heightened awareness, creating a consumer base that demands higher standards from supplement brands. Within this environment, joint health remains a high-priority category. As active lifestyles, desk-based work, and healthy aging all intersect, the demand for products that align with everyday mobility needs continues to grow. MobilityMD's focus on purity and purposeful formulation allows it to stand out in a competitive market where consumers are looking for supplements that are as trustworthy as they are functional. Discover why MobilityMD is part of the new wave of clean, ingredient-first wellness products in 2025. SECTION 7: THE PUBLIC DEBATE AROUND JOINT HEALTH SUPPLEMENTS – SIGNALS, SKEPTICISM, AND SATURATION The conversation around joint health supplements in 2025 is both active and divided. Supporters often point to the importance of staying proactive with mobility support, highlighting the role of clean, naturally derived ingredients in long-term wellness routines. They value brands that offer transparency and avoid unnecessary additives, seeing these products as part of a broader strategy to maintain active, comfortable movement. Skeptics, however, question whether supplements are necessary for everyone and emphasize the need for realistic expectations. They often stress that lifestyle habits — such as regular movement, balanced nutrition, and proper hydration — form the foundation of joint health, with supplementation serving as a complement rather than a replacement. Neutral observers see the market as one experiencing rapid expansion, but also increased scrutiny. With many brands competing for attention, consumers are becoming more selective, favoring companies that provide clear ingredient information and maintain a consistent focus on product integrity. For products like MobilityMD, standing out means continuing to align with the values of informed, wellness-conscious buyers while avoiding overreaching claims. SECTION 8: ABOUT MOBILITYMD MobilityMD was created with a clear mission — to offer a joint support supplement that prioritizes purity, ingredient transparency, and alignment with modern wellness values. The brand focuses on sourcing naturally derived components that have been historically discussed in wellness communities for their association with mobility and comfort, while avoiding unnecessary additives or synthetic fillers. Every aspect of the product, from formulation to packaging, reflects a commitment to integrity. MobilityMD positions itself not as a quick-fix solution, but as part of a balanced lifestyle that may include movement practices, mindful nutrition, and regular self-care. By maintaining a clear, educational approach to its ingredients and purpose, the brand builds trust with consumers seeking a supplement that fits seamlessly into their long-term wellness routines. In a supplement landscape crowded with exaggerated promises, MobilityMD stands out for its straightforward, ingredient-first philosophy — offering a choice for those who value both product quality and transparency. See how MobilityMD's ingredient-focused approach is resonating with today's wellness-conscious consumers. SECTION 9: CONTACT MobilityMD – Clean, Ingredient-First Joint Support – Clean, Ingredient-First Joint Support Email: [email protected] Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute medical advice, diagnosis, or treatment and has not been evaluated by the Food and Drug Administration (FDA). MobilityMD is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician or qualified healthcare provider before beginning any new supplement, routine, or health program. Some links in this release may be promotional in nature and may lead to third-party websites. The publisher or author may receive compensation through affiliate commissions if a purchase is made through these links. This compensation does not affect the price you pay and helps support continued research and content publication. Results described or implied may not be typical and should not be interpreted as guarantees. Statements made about ingredients or outcomes reflect public discussion and historical usage only, and are not endorsed by medical professionals or regulatory agencies. Always do your own research and make informed decisions. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
CNBC
5 hours ago
- CNBC
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says
Key Points The Food and Drug Administration is considering revoking its authorization of Pfizer's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC. The move could leave many kids with no available shots against the virus, though Moderna's shot will be an option for those at increased risk of severe illness due to at least one underlying condition. It would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, took the helm. In this article PFE Follow your favorite stocksCREATE FREE ACCOUNT A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine's Southern Cooking in Chatham, Illinois, Dec. 30, 2021. Brian Cassella | Tribune News Service | Getty Images The Food and Drug Administration is considering revoking its authorization of Pfizer 's Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization. If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr., a prominent vaccine skeptic, took the helm. HHS did not immediately respond to a request for comment. The FDA told Pfizer it might not renew its longstanding emergency use authorization for children ages 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is "currently in discussions with the agency on potential paths forward." The company said that the FDA's "deliberations" are not related to the safety and efficacy of the shot, "which continues to demonstrate a favorable profile." The Guardian first reported on the FDA's potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported Saturday. In July, the FDA granted full approval to Moderna's Covid vaccine for children — but only for those with one more more health conditions that may put them at increased risk of severe illness if they become infected. The shots from both Moderna and Pfizer use messenger RNA technology. Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs. Meanwhile, Novavax 's protein-based shot has never been available for children under 12. In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. But in updated guidance days later, the CDC said the shots "may" be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as "No Guidance/Not Applicable," where they were previously recommended for all pregnant adults.
USA Today
6 hours ago
- USA Today
Family sues for wrongful death in deadly listeria outbreak
A California family is suing for wrongful death in the wake of a listeria outbreak caused by nutrition shakes that led to the deaths of 14 people this year, including their relative. In February, the Food and Drug Administration (FDA) announced an investigation into an outbreak linked to Lyons ReadyCare and Sysco Imperial brand frozen supplemental shakes. At the time, Lyon Magnus LLC, the parent company, recalled 17 affected products. The contaminated shakes, distributed to long-term care facilities and hospitals, were produced by a Prairie Farms Dairy Inc. facility in Fort Wayne, Indiana. The FDA and Centers for Disease Control (CDC) declared the outbreak over on May 16. The agency reported 42 cases of listeriosis, or listeria poisoning, across 21 states, resulting in 41 hospitalizations and 14 deaths. The illnesses and deaths, which overwhelmingly (90%) occurred in people in care facilities or those who had been hospitalized before they became infected, were confirmed through whole genome sequencing as being caused by the outbreak strain associated with the shakes. Wrongful death suit alleges man died of listerosis complications The CDC began monitoring the outbreak of the disease as early as 2018, food safety lawyer Bill Marler told USA TODAY. At the beginning, epidemiologists were unable to identify the source of the illnesses. Now, with the outbreak technically over, some families are just beginning to find out their loved ones were victims, Marler said. Marler of the Marler Clark law firm said he's filed the first lawsuit related to the outbreak on Thursday, Aug. 7. It says the outbreak spanned multiple years and was likely the result of conditions within one of the manufacturing and packaging facilities. Marler said that the family who sued was not informed until July that their relative's death was caused by the outbreak. The wife and children of John Wills Sr. of Richmond, California, sued Lyon, the distributor of the shakes, and Prairie Farms Dairy Inc., the manufacturer. Their suit said Wills was recovering from a slip-and-fall injury in a local care facility when, on July 20, 2024, he was given a contaminated shake. Wills, who was previously able to move with the assistance of a mobility device, to participate in physical therapy and eat meals normally, soon developed a fever, pain and had difficulty speaking, according to the suit. After multiple hospitalizations and monitoring for infectious disease, Wills died of "complications related to his Listeria infection and other comorbid conditions" on Feb. 22, 2025. His relatives are seeking damages and payment of Wills' medical and legal fees. Marler criticized the CDC and FDA for their reporting practices, telling USA TODAY and explaining in a blog post that victims like Wills underwent various tests – including blood and spinal fluid draws – and underwent investigations that involved family interviews and reviews of purchase histories. However, they were never informed by the agencies about the cause of their illness or death. "I spoke with a family today to inform them that their husband/father died after suffering a Listeria infection," Marler said in a recent blog post shared with USA TODAY, which he confirmed was referencing Wills. "Until today, the family did not know the cause of his infection despite (the) fact that it has been known by local, state and federal officials for over a year." USA TODAY has reached out to the CDC and FDA for comment. Which states had listeria poisoning cases? A total of 21 states had known listeria outbreaks related to this recall: Alabama, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Michigan, Minnesota, Missouri, North Carolina, Nevada, New York, Ohio, Oklahoma, Pennsylvania, Tennessee, Texas, Washington, and West Virginia. The 14 deaths occurred in nine states: California, Illinois, Indiana, Michigan, Minnesota, North Carolina, New York, Tennessee, Texas, and Washington. Which Lyons ReadyCare and Sysco Imperial shakes were recalled? All recalled products had "best buy" dates between 02/21/25 and 02/21/26, according to Lyons Magnus. All the contaminated products are believed to have been destroyed, the FDA notice said. What is listeriosis or listeria poisoning? Listeriosis, or listeria poisoning, is a foodborne bacterial infection most commonly caused by the bacterium Listeria monocytogenes. It is considered a serious condition and can be dangerous or life-threatening, especially to older adults, people with weak immune systems and pregnant people. Signs and symptoms of listeriosis may not appear until weeks after consumption. Persons in the higher-risk categories who experience flu-like symptoms within two months after eating contaminated food should seek medical care and tell their health care provider about eating the contaminated food, according to the U.S. Department of Agriculture. According to the USDA, symptoms include:
